Skip to main content
Advertisement
  • Loading metrics

Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV

  • Alison L. Hill,
  • Daniel I. S. Rosenbloom,
  • Edward Goldstein,
  • Emily Hanhauser,
  • Daniel R. Kuritzkes,
  • Robert F. Siliciano,
  • Timothy J. Henrich
  • Article
  • Metrics
  • Comments
  • Media Coverage

S3 Text is missing the reference list. The missing references are as follows:

[1]Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, et al. Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies. PLoS Pathog. 2013 Feb;9(2):e1003174. Available from: http://dx.doi.org/10.1371/journal.ppat.1003174.

[2]Crooks AM, Bateson R, Cope AB, Dahl NP, Griggs MK, Kuruc JD, et al. Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. Journal of Infectious Diseases. 2015 Apr;p. jiv218. Available from: http://jid.oxfordjournals.org/content/early/2015/04/15/infdis.jiv218.

[3]Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies con_rm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003 Jun;9(6):727{728. Available from: http://dx.doi.org/10.1038/nm880.

[4]Hill AL, Rosenbloom DIS, Fu F, Nowak MA, Siliciano RF. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci USA. 2014 Sep;111(37):13475{13480. Available from: http://www.pnas.org/content/111/37/13475.

[5]Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DIS, et al. ReplicationCompetent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure. Cell. 2013 Oct;155(3):540{551. PMID: 24243014.

[6]Archin NM, Vaidya NK, Kuruc JD, Liberty AL, Wiegand A, Kearney MF, et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci USA. 2012 Jun;109(24):9523{9528.

[7]Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, Zhang H, et al. Dose-response curve slope sets class-speci_c limits on inhibitory potential of anti-HIV drugs. Nature medicine. 2008;14(7):762766.

[8]Jilek BL, Zarr M, Sampah ME, Rabi SA, Bullen CK, Lai J, et al. A quantitative basis for antiretroviral therapy for HIV-1 infection. Nature Medicine. 2012 Feb;18(3):446{451. Available from: http://www.nature.com/nm/journal/v18/n3/full/nm.2649.html.

[9]Henrich TJ, Hu Z, Li JZ, Sciaranghella G, Busch MP, Keating SM, et al. Long-Term Reduction in Peripheral Blood HIV-1 Reservoirs Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. Journal of Infectious Diseases. 2013 Jun;207(11):1694{1702. Available from: http://jid.oxfordjournals.org/content/early/2013/02/28/infdis.jit086.

[10]Sedaghat AR, Siliciano JD, Brennan TP, Wilke CO, Siliciano RF. Limits on Replenishment of the Resting CD4+ T Cell Reservoir for HIV in Patients on HAART. PLoS Pathog. 2007;3(8):e122. Available from: http://dx.plos.org/10.1371/journal.ppat.0030122.

[11]Nettles R, Kie_er TL, Kwon P, Monie D, Han Y, Parsons T, et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA. 2005 Feb;293(7):817{829. Available from: http://dx.doi.org/10.1001/jama.293.7.817.

[12]Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, et al. Treatment intensi_cation does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA. 2009;106(23):9403.

The corrected S3 Text is provided here.

Supporting information

S3 Text. Estimating the size and source of the reservoir post-transplant.

https://doi.org/10.1371/journal.ppat.1006488.s001

(PDF)

Reference

  1. 1. Hill AL, Rosenbloom DIS, Goldstein E, Hanhauser E, Kuritzkes DR, Siliciano RF, et al. (2016) Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV. PLoS Pathog 12(4): e1005535. pmid:27119536